key: cord-0683602-hr6ied4c authors: Dai, Xiaofeng title: ABO blood group predisposes to COVID-19 severity and cardiovascular diseases date: 2020-09-01 journal: Eur J Prev Cardiol DOI: 10.1177/2047487320922370 sha: d308a9cb1aa25e0225533600009efcd28c4b6d21 doc_id: 683602 cord_uid: hr6ied4c nan Ever since the first outbreak in Wuhan China December 2019, novel coronavirus disease has rapidly spread to many other regions and become a global health threat. So far, COVID-19 has affected over 200 countries and the mortality rate reached as high as 8% in Italy. 1 The novel pathological agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), uses angiotensin-converting enzyme 2 (ACE2) during transmission. 2 One important epidemiological clinical characteristic of COVID-19 is the enrichment of severe patients with cardiovascular disease carriers especially hypertension. 3 Hypertension is the global leading cause of mortality and represents the most important factor predisposing the risk of developing cardiovascular diseases. Hypertensive patients typically have over-elevated ACE/ANGII axis, in which ACE positively regulates the level of angiotensin II (ANGII) in the renin-angiotensin-aldosterone system (RAS). Drugs that inhibit the RAS, namely ACE inhibitors and angiotensin receptor antagonists (ARAs), are common medications for hypertension management. 4 While ACE is hypertension promoting, ACE2 counterbalances the effects of ACE and delivers many beneficial effects to human health including attenuating inflammatory response and redox stress. 5 It was reported that the ABO blood group is associated with ACE activity and ACE inhibitor-induced cough among Chinese patients with essential hypertension. 6, 7 That is, the GATC haplotype of the four polymorphisms of the ABO gene (rs8176746, rs8176740, rs495828, rs12683493), which is prevalent among non-O blood type patients, is positively associated with ACE activity. 6 Thereby, O blood type carriers should have lower ACE levels and a higher probability of enjoying protection from ACE2-conveyed benefits. Consistent with this, blood type O carriers have a higher interleukin 6 (IL-6) level than non-type O carriers. 8 IL-6 is a proinflammatory cytokine triggering the production of acute-phase proteins such as C-reactive protein. As higher levels of C-reactive protein were detected among ACE-inhibitor-induced coughers than controls, 9 we would expect a positive relationship between IL-6 secretion and ACE inhibitor and/or ACE2. A genome-wide association study (GWAS) found that blood type O carriers have increased IL-6 levels than individuals carrying the other blood group types, 8 suggesting the advantages of blood type O over the other types in maintaining the dominant role of ACE2 in the RAS and thus a reduced risk of developing hypertension. On the contrary, the A allele of the ABO blood group has been associated with an increased risk of developing cardiovascular diseases as reported by several studies. 10 The A antigen might protect P-selectin and intercellular cell adhesion molecule 1 (ICAM1) from enzymatic cleavage by promoting stronger and longer binding of leukocytes to them on the vascular wall; more adhesion molecules attached to the endothelial cells would on one hand increase adhesion and inflammation but on the other hand decrease circulation. 11 These collectively predispose type A carriers to a higher likelihood of developing cardiovascular diseases and aggregate disease situations once these individuals were exposed to redox stresses such as in the case of virus infection. Therefore, individuals having an O blood group type are less likely to develop cardiovascular diseases and severe COVID-19 and, on the contrary, patients carrying an A blood group type, especially those already having been diagnosed with cardiovascular diseases in particular hypertension, are more likely to develop severe COVID-19 once infected (Figure 1 ). These individuals need to be quarantined and protected from SARS-CoV-2 infection or under special medical care to be prevented from deterioration and severe progression. Although ABO blood type and/or cardiovascular diseases are prognostic of COVID-19 patient severity, they are not risk factors predisposing to the risk of getting SARS-CoV-2 infection. This is attributable to the dual roles played by ACE2 (the primary receptor mediating SARS-CoV-2 cell entry), that is, mediating SARS-CoV-2 entry and being protective against cardiovascular diseases, which makes COVID-19 risk and severity a pair of paradoxes. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Blood O type is protective against the development of cardiovascular diseases and severe COVID-19 as it is associated with lower angiotensin-converting enzyme (ACE) level and higher ACE2 activity. Blood A type is risky for the development of cardiovascular diseases and severe COVID-19 due to: (a) its positive association with ACE activity, and (b) the attachment of adhesion molecules on the vascular wall that increases inflammation and decreases blood circulation. Geneva: World Health Organization Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China Clinical characteristics of coronavirus disease 2019 in China RAS inhibition in hypertension Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-kappaB and Nrf2 pathways Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitorsinduced cough ABO(H) blood groups and vascular disease: a systematic review and meta-analysis Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women The author(s) received no financial support for the research, authorship, and/or publication of this article.